Amplia Therapeutics Ltd.ASX: ATX

FDA Clearance Amplia's IND for Pancreatic Cancer Trial in US

· Issued by Amplia Therapeutics Ltd.

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Amplia Therapeutics Ltd. has received clearance from the US FDA for its Investigational New Drug application for a clinical trial of narmafotinib in pancreatic cancer patients. The trial will investigate the combination of narmafotinib with the chemotherapy regimen FOLFIRINOX, which is commonly used in the US. This clearance marks a significant advancement for Amplia as it expands the clinical opportunities for narmafotinib.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Amplia Therapeutics Ltd. on 6ix

Story so far

Earlier from Amplia Therapeutics

Later from Amplia Therapeutics

All Amplia Therapeutics news releases